Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1950 2
1952 1
2006 1
2007 1
2010 2
2012 1
2013 2
2014 1
2016 1
2018 2
2019 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Neuromuscular blockers in early acute respiratory distress syndrome.
Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, Jaber S, Arnal JM, Perez D, Seghboyan JM, Constantin JM, Courant P, Lefrant JY, Guérin C, Prat G, Morange S, Roch A; ACURASYS Study Investigators. Papazian L, et al. N Engl J Med. 2010 Sep 16;363(12):1107-16. doi: 10.1056/NEJMoa1005372. N Engl J Med. 2010. PMID: 20843245 Free article. Clinical Trial.
Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs.
Santamarina E, Bertol V, Garayoa V, García-Gomara MJ, Garamendi-Ruiz I, Giner P, Aranzábal I, Piera A, Arcos C, Esteve P, Marinas A, García-Escrivá A, Viloria-Alebesque A, Loro FA, de Tienda AP, Olivan JA, Bonet M, Dávila-González P, Sivera R, Molins A, Sansa G, Roche JC, Martínez AB, Monteagudo S, Casadevall T. Santamarina E, et al. Among authors: piera a. Seizure. 2020 Dec;83:48-56. doi: 10.1016/j.seizure.2020.09.026. Epub 2020 Oct 7. Seizure. 2020. PMID: 33096456 Free article.
A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors.
Capdevila J, Clive S, Casado E, Michie C, Piera A, Sicart E, Carreras MJ, Coronado C, Kahatt C, Soto Matos-Pita A, Fernandez Teruel C, Siguero M, Cullell-Young M, Tabernero J. Capdevila J, et al. Among authors: piera a. Cancer Chemother Pharmacol. 2013 May;71(5):1247-54. doi: 10.1007/s00280-013-2119-8. Epub 2013 Mar 2. Cancer Chemother Pharmacol. 2013. PMID: 23455428 Clinical Trial.
NEOPLASM study: Real-life use of lacosamide in patients with brain tumor-related epilepsy.
Villanueva V, Saiz-Diaz R, Toledo M, Piera A, Mauri JA, Rodriguez-Uranga JJ, López-González FJ, Gómez-Ibáñez A, Garcés M, González de la Aleja J, Rodríguez-Osorio X, Palao-Duarte S, Castillo A, Bonet M, Ruiz-Giménez J, Palau J, Arcediano A, Toledo M, Gago A. Villanueva V, et al. Among authors: piera a. Epilepsy Behav. 2016 Dec;65:25-32. doi: 10.1016/j.yebeh.2016.09.033. Epub 2016 Nov 16. Epilepsy Behav. 2016. PMID: 27863278
Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.
Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, Roselló S, Andreu J, Jung J, Sanchis-Garcia JM, Piera A, Blasco I, Maños L, Pérez-Fidalgo JA, Fingert H, Baselga J, Tabernero J. Cervantes A, et al. Among authors: piera a. Clin Cancer Res. 2012 Sep 1;18(17):4764-74. doi: 10.1158/1078-0432.CCR-12-0571. Epub 2012 Jul 2. Clin Cancer Res. 2012. PMID: 22753585 Clinical Trial.
Factors influencing response to intravenous lacosamide in emergency situations: LACO-IV study.
Garcés M, Villanueva V, Mauri JA, Suller A, García C, López González FJ, Rodríguez Osorio X, Fernández Pajarín G, Piera A, Guillamón E, Santafé C, Castillo A, Giner P, Torres N, Escalza I, Del Villar A, García de Casasola MC, Bonet M, Noé E, Olmedilla N. Garcés M, et al. Among authors: piera a. Epilepsy Behav. 2014 Jul;36:144-52. doi: 10.1016/j.yebeh.2014.05.015. Epub 2014 Jun 10. Epilepsy Behav. 2014. PMID: 24922617
Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study.
Villanueva V, Montoya J, Castillo A, Mauri-Llerda JÁ, Giner P, López-González FJ, Piera A, Villanueva-Hernández P, Bertol V, Garcia-Escrivá A, Garcia-Peñas JJ, Garamendi I, Esteve-Belloch P, Baiges-Octavio JJ, Miró J, Falip M, Garcés M, Gómez A, Gil-López FJ, Carreño M, Rodriguez-Uranga JJ, Campos D, Bonet M, Querol R, Molins A, Tortosa D, Salas-Puig J. Villanueva V, et al. Among authors: piera a. Epilepsia. 2018 Sep;59(9):1740-1752. doi: 10.1111/epi.14522. Epub 2018 Jul 31. Epilepsia. 2018. PMID: 30062784
Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.
Eskens FA, Ramos FJ, Burger H, O'Brien JP, Piera A, de Jonge MJ, Mizui Y, Wiemer EA, Carreras MJ, Baselga J, Tabernero J. Eskens FA, et al. Among authors: piera a. Clin Cancer Res. 2013 Nov 15;19(22):6296-304. doi: 10.1158/1078-0432.CCR-13-0485. Epub 2013 Aug 27. Clin Cancer Res. 2013. PMID: 23983259 Clinical Trial.
16 results